Technology suppliers are currently focused on removing technical burdens to allow smaller biotech firms to access high-level efficiency and reproducibility. The biomanufacturing industry stands at a critical juncture where the simple accumulation of biological data no longer provides a competitive
Scaling up carbon removal requires a transparent monitoring framework, which is provided by the predictable stoichiometric ratios of mineral-based alkalinity generation. As the world moves through 2026, the urgency of the climate crisis has shifted the global conversation from simple emissions
Mapping the adult human intestine through spatial atlases is essential for bridging the biological gap between mouse models and human clinical applications. The human intestine remains one of the most biologically active environments in the body, defined by a relentless and necessary cycle of
Bora Biologics has executed over 200 cGMP batches to date, including more than 60 batches dedicated specifically to commercial supply programs. This extensive experience addresses a critical challenge in modern medicine: the need for reliable, high-speed diagnostic tools that can keep pace with an
Vascularization remains a critical biotechnological hurdle for the industry, as thick tissue cuts cannot survive without internal systems to deliver nutrients and remove waste. This fundamental challenge defines the current landscape of cellular agriculture in 2026, as scientists move beyond basic
Strategic use of digital shadows allows engineers to run what-if simulations without risking the integrity of a physical production batch during development. This capability marks a dramatic departure from the era when biological manufacturing was as much an art form as it was a science. In the
